Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis

6 Research Recommendations

6.1 The Committee recommends further research to better inform future cost‑effectiveness models of relapsing‑remitting multiple sclerosis. In particular, this research should include a more comprehensive synthesis of available evidence on the underlying disease progression of multiple sclerosis in the UK context, the impact of disability and relapses on preference‑based measures of quality of life, and associated resource use and costs.